Amgen's Q2 2012 earnings call contained strong signals of continued growth and a positive outlook.  Management highlighted strong revenue growth, increases in EPS, and a raise in guidance for the year.  The call emphasized upcoming Phase III trials for key pipeline products like AMG 785 and AMG 145, suggesting significant future investment and potential for further growth.
[2]
